Product safety
Patient safety is a priority concern for Nanolek, both at the drug development stage and after the drug has been registered and is widely used in medical practice.
In accordance with the Russian law, international standards and ethical principles, the company monitors the safety of the drug use to identify possible adverse reactions and other clinically relevant information associated with the use of all Nanolek drugs.
The main objectives of pharmacovigilance are the earliest possible identification of previously unknown drug safety issues, identification of changes in the incidence of adverse reactions, determination of risk factors related to the drug use and their quantitative assessment, and monitoring of the risk-benefit ratio.
Safety monitoring ensures timely reporting to regulatory authorities and health professionals of adverse reactions associated with the use of company products and helps minimize the risks associated with their use, thus ensuring patient safety during treatment.
Please inform us immediately if you become aware of:
- any adverse events arising from the drug use;
- cases of overdose;
- drug-to-drug interactions and interactions with food products;
- the off-label use of drugs (contrary to instructions for medical use);
- inefficacy of drugs;
- the use of drugs during pregnancy or lactation, if it is prohibited by the instructions for medical use; unexpected therapeutic effects of drugs.
HOW TO REPORT ON THE SAFETY OF OUR MEDICINAL PRODUCTS:
Please describe in detail the course of adverse reactions and provide information about the patient and his/her medical history. Only accurate and detailed information will help identify adverse reactions and determine their relationship with simultaneously used drugs.
Please immediately report any issue:
- by phone+7(495)648-26-87
or by sending an email to safety@nanolek.ru
All personal data are processed according to the principles and rules defined by Federal Law No.152-FZ "On personal data"
Please download the questionnaire and send the completed form by
fax +7(495)648-26-87
or by sending an email to safety@nanolek.ru - or by mail 127055, Moscow,
Butyrsky Val, 68/70, bldg. 1.
Baker Plaza Business Center,
2nd floor, office 24